| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The primary target of 3,7-DMF is the TGF-beta1 signaling pathway in hepatic stellate cells (HSCs). It acts as an inhibitor of TGF-beta1-induced HSC activation, a key event in the pathogenesis of liver fibrosis. By blocking this pathway, it prevents the transdifferentiation of HSCs into fibrogenic myofibroblasts.
|
|---|---|
| ln Vitro |
In vitro, 3,7-DMF effectively inhibits the activation of hepatic stellate cells induced by the pro-fibrotic cytokine TGF-beta1. It upregulates the expression of antioxidant genes and reduces the levels of reactive oxygen species (ROS), creating a cellular environment that suppresses the fibrotic response.
|
| ln Vivo |
In vivo, 3,7-DMF is an orally active compound that can be utilized to study liver fibrosis. By inducing antioxidant genes and quenching ROS, it reduces oxidative stress and inhibits the TGF-beta1-driven activation of HSCs. Its oral bioavailability makes it a practical tool for intervention studies in animal models of chronic liver disease.
|
| Enzyme Assay |
Cell-free assays for 3,7-DMF focus on its antioxidant capacity. The compound's ability to quench ROS is measured by incubating it with a known free-radical generator (e.g., ABTS or DPPH). The reduction in the radical's characteristic absorbance at a specific wavelength (e.g., 517 nm for DPPH) is measured spectrophotometrically to determine its antioxidant potential.
|
| Cell Assay |
Cellular assays are performed using primary hepatic stellate cells (HSCs) or the immortalized human HSC line (LX-2). Cells are serum-starved and then pre-treated with 3,7-DMF for 1-2 hours, followed by stimulation with TGF-beta1 (2-5 ng/mL) for 24-48 hours. HSC activation is measured by Western blot for alpha-SMA, collagen I, and fibronectin. Intracellular ROS levels are measured using a fluorescent probe (e.g., DCFH-DA).
|
| Animal Protocol |
In vivo studies are conducted in rodent models of liver fibrosis, typically induced by chronic administration of carbon tetrachloride (CCl4) or by bile duct ligation (BDL). Mice or rats are treated with 3,7-DMF via daily oral gavage for 4-8 weeks. At study termination, liver tissues are harvested for histological analysis (Sirius Red staining), measurement of hydroxyproline content, and assessment of alpha-SMA and collagen gene expression by qPCR.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of 3,7-DMF are favorable for research applications, as it is reported to be an orally bioavailable compound. This property is critical for its use in chronic in vivo studies, allowing for convenient and reproducible dosing in animal models of liver fibrosis.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 3,7-DMF is not well-documented in publicly available literature. As a flavone derivative, it is generally considered to have low toxicity. Safety assessments are ongoing, but it is intended for research use only, and standard precautions for handling chemicals should be followed.
|
| References | |
| Additional Infomation |
3,7-Dimethoxy-2-phenyl-1-benzopyran-4-one belongs to the flavonoid class of compounds, which is an ether compound. It has been reported that 3,7-dimethoxyflavonoids have been found in Pongamia pinnata, and relevant data are available for reference.
3,7-DMF (3,7-Dimethoxyflavone) has a molecular formula of C17H14O4 and a molecular weight of 282.29. It is a pure, well-defined chemical compound, not an extract. This compound is a valuable tool for studying the molecular mechanisms of liver fibrosis and for the preclinical evaluation of potential drug candidates for this condition. |
| Molecular Formula |
C17H14O4
|
|---|---|
| Molecular Weight |
282.29
|
| Exact Mass |
282.089
|
| CAS # |
20950-52-1
|
| PubChem CID |
688664
|
| Appearance |
White to off-white solid
|
| LogP |
3.477
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
423
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1C(=O)C2C(=CC(OC)=CC=2)OC=1C1C=CC=CC=1
|
| InChi Key |
CNDZOPXQZSXGSK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H14O4/c1-19-12-8-9-13-14(10-12)21-16(17(20-2)15(13)18)11-6-4-3-5-7-11/h3-10H,1-2H3
|
| Chemical Name |
3,7-dimethoxy-2-phenylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~16.7 mg/mL (~59.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (5.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (16.7 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5425 mL | 17.7123 mL | 35.4246 mL | |
| 5 mM | 0.7085 mL | 3.5425 mL | 7.0849 mL | |
| 10 mM | 0.3542 mL | 1.7712 mL | 3.5425 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
